Seaport Therapeutics, Inc. Form 10-Q — Nov 2, 2026
Seaport Therapeutics (Nasdaq: SPTX) filed its first 10-Q as a public company, reporting a Q3 2026 net loss of $26.4 million and a nine-month net loss of $114.4 million, versus $50.7 million in the prior-year period. The company completed its IPO in May 2026, selling 14.4 million shares at $18.00 for roughly $238.4 million in net proceeds, and had $403.8 million in cash, equivalents and investments at quarter end. Management believes that cash is sufficient to fund operations into 2029.
Key figures
- Net Loss
- 114402000
- Total Assets
- 417624000
- Cash Position
- 403800000
- Gross Proceeds
- 238400000
- Shares Outstanding
- 53530550
- Ipo price
- 18
- Cash runway
- into 2029
- Q3 net loss
- 26394000
- Arpa h award
- 15200000
- Q3 rnd expense
- 23891000
- Ipo shares sold
- 14446658
- Accumulated deficit
- 228511000
- Q3 stock based comp
- 2448000
- Reverse split ratio
- 1-for-3.1407
- Nine month rnd expense
- 69939000
- Series b gross proceeds
- 226000000
- Series a2 gross proceeds
- 100100000
- Nine month stock based comp
- 41880000
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.